BlackRock
CTNM

BlackRock’s Contineum Therapeutics CTNM Stock Holding History

BlackRock’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8M Buy
2,064,345
+1,395,222
+209% +$18.3M ﹤0.01% 2916
2026
Q1 		$8.74M Buy
669,123
+132,968
+25% +$1.78M ﹤0.01% 3582
2025
Q4 		$6.13M Buy
536,155
+214,124
+66% +$2.44M ﹤0.01% 3752
2025
Q3 		$3.78M Buy
322,031
+156,585
+95% +$1.26M ﹤0.01% 3895
2025
Q2 		$657K Sell
165,446
-451,178
-73% -$1.96M ﹤0.01% 4381
2025
Q1 		$4.3M Buy
616,624
+13,047
+2% +$119K ﹤0.01% 3700
2024
Q4 		$8.84M Buy
603,577
+198,805
+49% +$3.15M ﹤0.01% 3488
2024
Q3 		$7.75M Buy
404,772
+8,499
+2% +$163K ﹤0.01% 3535
2024
Q2 		$6.98M Buy
+396,273
New +$6.38M ﹤0.01% 3564

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BlackRock's CTNM Position: Q2 2026 in Review

BlackRock increased its Contineum Therapeutics (CTNM) stake by 209% in Q2 2026, buying an estimated $18.3M and bringing the position to 2,064,345 shares worth $33.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

BlackRock first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • BlackRock held 2,064,345 shares of Contineum Therapeutics worth $33.8M as of Q2 2026.
  • BlackRock bought 1,395,222 Contineum Therapeutics shares in Q2 2026, an estimated $18.3M.
  • Contineum Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2916 holding.
  • BlackRock first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.